Literature DB >> 22239669

Waldenström macroglobulinemia: a Surveillance, Epidemiology, and End Results database review from 1988 to 2005.

Jeevan Sekhar, Kristen Sanfilippo, Qin Zhang, Kathryn Trinkaus, Ravi Vij, Daniel Morgensztern.   

Abstract

Entities:  

Mesh：

Year:  2012        PMID： 22239669     DOI： 10.3109/10428194.2012.656103

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  16 in total

Review 1.  Toward personalized treatment in Waldenström macroglobulinemia.

Authors:  Jorge J Castillo; Steven P Treon
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

Review 2.  The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström's Macroglobulinemia.

Authors:  Abdullah Mohammad Khan
Journal:  J Pers Med       Date:  2022-04-22

Review 3.  Etiology of Waldenström macroglobulinemia: genetic factors and immune-related conditions.

Authors:  Elisabet E Manasanch; Sigurdur Y Kristinsson; Ola Landgren
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2013-03-07

4.  Immunophenotyping of Waldenströms macroglobulinemia cell lines reveals distinct patterns of surface antigen expression: potential biological and therapeutic implications.

Authors:  Aneel Paulus; Kasyapa S Chitta; Paul K Wallace; Pooja P Advani; Sharoon Akhtar; Maja Kuranz-Blake; Sikander Ailawadhi; Asher A Chanan-Khan
Journal:  PLoS One       Date:  2015-04-08       Impact factor: 3.240

5.  Waldenström macroglobulinemia with extramedullary involvement at initial diagnosis portends a poorer prognosis.

Authors:  Xin Cao; Qing Ye; Robert Z Orlowski; Xiaoxiao Wang; Sanam Loghavi; Meifeng Tu; Sheeba K Thomas; Jatin Shan; Shaoying Li; Muzaffar Qazilbash; C Cameron Yin; Donna Weber; Roberto N Miranda; Zijun Y Xu-Monette; L Jeffrey Medeiros; Ken H Young
Journal:  J Hematol Oncol       Date:  2015-06-24       Impact factor: 17.388

6.  Coinhibition of the deubiquitinating enzymes, USP14 and UCHL5, with VLX1570 is lethal to ibrutinib- or bortezomib-resistant Waldenstrom macroglobulinemia tumor cells.

Authors:  A Paulus; S Akhtar; T R Caulfield; K Samuel; H Yousaf; Y Bashir; S M Paulus; D Tran; R Hudec; D Cogen; J Jiang; B Edenfield; A Novak; S M Ansell; T Witzig; P Martin; M Coleman; V Roy; S Ailawadhi; K Chitta; S Linder; A Chanan-Khan
Journal:  Blood Cancer J       Date:  2016-11-04       Impact factor: 11.037

Review 7.  Waldenstrom's Macroglobulinemia: An Update.

Authors:  Maddalena Mazzucchelli; Anna Maria Frustaci; Marina Deodato; Roberto Cairoli; Alessandra Tedeschi
Journal:  Mediterr J Hematol Infect Dis       Date:  2018-01-01       Impact factor: 2.576

Review 8.  New developments in the management of Waldenström macroglobulinemia.

Authors:  Jithma P Abeykoon; Uday Yanamandra; Prashant Kapoor
Journal:  Cancer Manag Res       Date:  2017-03-10       Impact factor: 3.989

9.  Incidence, prevalence, mortality, and causes of death in Waldenström macroglobulinemia: a nationwide, population-based cohort study.

Authors:  Seri Jeong; Seom Gim Kong; Da Jung Kim; Sangjin Lee; Ho Sup Lee
Journal:  BMC Cancer       Date:  2020-07-03       Impact factor: 4.430

Review 10.  Waldenström macroglobulinemia: clinical and immunological aspects, natural history, cell of origin, and emerging mouse models.

Authors:  Siegfried Janz
Journal:  ISRN Hematol       Date:  2013-09-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.